Intraoperative Folate-fluorescein Conjugate (EC17) Lung Cancer (CA)

This study is currently recruiting participants.
Verified November 2013 by University of Pennsylvania
Information provided by (Responsible Party):
Sunil Singhall, University of Pennsylvania Identifier:
First received: January 18, 2013
Last updated: November 21, 2013
Last verified: November 2013

January 18, 2013
November 21, 2013
April 2012
April 2015   (final data collection date for primary outcome measure)
The ability of the imaging system to detect the expression of EC17 in the nodule/mass (i.e. tumor) and discern the uptake of the dye by the tumor [ Time Frame: Within two hours of injection of the EC17 ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT01778920 on Archive Site
The number of participants that will have an adverse reaction to the EC17 [ Time Frame: Day 1 - Day 30 ] [ Designated as safety issue: Yes ]
Same as current
Not Provided
Not Provided
Intraoperative Folate-fluorescein Conjugate (EC17) Lung Cancer (CA)
Pilot and Feasibility Study of the Imaging Potential of EC17

According to the World Health Organization, lung cancer is the most common cause of cancer-related death in men and women, and is responsible for 1.3 million deaths worldwide annually as of 2004. Surgery remains the best option for patients presenting with operable Stage I or II cancers, however the five year survival rate for these candidates remains at a dismal 53% for Stage I and 32% for Stage II. The high rates of recurrence suggest that surgeons are unable to completely detect and remove primary tumor nodules in a satisfactory manner as well as lingering metastases in sentinel lymph nodes. By ensuring a negative margin through imaging during surgery it would be possible for us to improve the rates of recurrence free patients and thus overall survival.

Thoracic malignancies are the ideal disease to investigate intra-operative imaging. Over 85% of lung and pleural malignancies express folate receptor alpha (FRA), and a fluorescent probe targeting FRA is readily available. It is important to note that FRA is expressed only in the proximal tubules of the kidneys, activated macrophages, and in the choroidal plexus. Thus, the false positive detection rate is expected to be extremely low. A group well known to us in the Netherlands has completed a pilot study utilizing a folate- fluorescein-5-isothiocyanate (FITC) conjugate in 12 patients with ovarian cancer. They have subsequently performed this study on 20 more patients without any adverse events (personal communication). They report excellent sensitivity and specificity with this technique with only grade 1 side effects (allergic reaction). All side effects reversed when the injection was halted. The only known allergy is those patients which have an insect reaction (fluorescein is derived from the firefly insect, folate is an essential vitamin). This drug has also been used at a higher dose for therapeutic purposes in patients with metastatic renal cell carcinoma in the United States. However, this drug will be used at a lower dose for a diagnostic purpose only.

Not Provided
Phase 1
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Diagnostic
  • Lung and Pleural Malignancies
  • Neoplasms
  • Nodules
Drug: EC17
Experimental: IV Injection of EC17
This group will receive a single dose of EC17, infused over 10 minutes, prior to surgery. Then, during surgery, they will be imaged with the camera and imaging probe the investigators have developed
Intervention: Drug: EC17
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Not Provided
April 2015   (final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Adult patients over 18 years of age
  2. Patients presenting with a lung or pleural nodule or mass presumed to be resectable on pre-operative assessment
  3. Good operative candidate
  4. Subject capable of giving informed consent and participating in the process of consent.

Exclusion Criteria:

  1. Pregnant women as determined by urinary or serum beta human chorionic gonadotropin (hCG) within 72 hours of surgery
  2. Patients with a history of anaphylactic reactions to Folate-FITC or insects
  3. At-risk patient populations

    1. Homeless patients
    2. Patients with drug or alcohol dependence
    3. Children and neonates
    4. Patients unable to participate in the consent process
18 Years and older
Contact: Sunil Singhal, M.D.
United States
EC17 Lung Cancer, 815058
Sunil Singhall, University of Pennsylvania
University of Pennsylvania
Not Provided
Principal Investigator: Sunil Singhal, M.D. University of Pennsylvania
University of Pennsylvania
November 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP